Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphopenia 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Hematologic Diseases 1Esophageal Neoplasms 1Agammaglobulinemia 1

Interventions

fludarabine 12Cyclophosphamide 11Busulfan 8Mycophenolic Acid 6Dexamethasone 6fludarabine phosphate 5Whole-Body Irradiation 5Tacrolimus 5Melphalan 5Lenalidomide 5Granulocyte Colony-Stimulating Factor 4isatuximab 3Thiotepa 3Sirolimus 3Rituximab 3Methotrexate 3Cyclosporine 3Blood Specimen Collection 3Alemtuzumab 3pomalidomide 2pembrolizumab 2daratumumab 2Vorinostat 2Stem Cell Transplantation 2Platelet Transfusion 2Ondansetron 2Interviews as Topic 2Filgrastim 2Exercise 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Diseases × SARS-CoV-2 inactivated vaccines × Clear all
NCT01924169 2018-09-20

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Hematologic Diseases, Influenza, Human, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡